Introduction
============

Genetic defects in the three SH3 and multiple ankyrin repeat domains (SHANK) genes (*SHANK1, SHANK2*, and *SHANK3*) are associated with multiple major neuropsychiatric disorders, including autism spectrum disorder (ASD), schizophrenia (SCZ), and bipolar disorder (BPD; [@B38]; [@B6]; [@B12]). Early genetic studies provided compelling evidence implicating *SHANK* mutations in the whole spectrum of ASD ([@B19]; [@B57]; [@B32]; [@B5]; [@B73]; [@B84]). However, there is increasing evidence suggesting that *SHANK* mutations play a prominent role in other neuropsychiatric disorders as well. For instance, [@B27] reported a *de novo SHANK1* frameshift mutation in a SCZ patient, and [@B48] found that a *SHANK1* promotor variant is associated with reduced auditory working memory capacity in SCZ patients. Mutations in *SHANK2* and *SHANK3* have likewise been described in individuals with SCZ ([@B31]; [@B72]; [@B41]). Moreover, a duplication in *SHANK2* has been reported for a BPD patient ([@B62]) and BPD has been diagnosed also in individuals with the Phelan-McDermid 22q13 deletion syndrome lacking *SHANK3* ([@B92]; [@B108]; [@B13]; [@B101], [@B102]; [@B103]). It thus appears that *SHANK* mutations are shared across multiple neuropsychiatric disorders similar to other genetic risk factors, pointing to extensive pleiotropy and challenging the biological validity of existing diagnostic approaches ([@B121]; [@B34]; [@B63]). However, the neurobiological mechanisms underlying the pleiotropic effects of *SHANK* mutations are not well understood.

The three *SHANK* genes code for several mRNA splice variants and generate multiple protein isoforms ([@B99]; [@B81]). Members of the SHANK protein family have five conserved protein domains through which they assemble into large molecular platforms in the postsynaptic density (PSD) at excitatory glutamatergic synapses. More than 30 synaptic proteins have been reported to form interactions with SHANK protein family members. As master scaffolding proteins, SHANKs anchor glutamate receptors and link them to the actin cytoskeleton and postsynaptic signaling pathways. They are thus strongly involved in several synaptic functions, including spine morphogenesis, synapse formation, glutamate receptor trafficking, and activity-dependent neuronal signaling.

Several *Shank* mouse models were generated during the last decade ([@B46]; [@B118]; [@B88]). While *Shank2* and *Shank3* mutant mice have been extensively characterized ([@B69]; [@B105]; [@B87]; [@B113]), comparatively little is known about *Shank1* mutant mice ([@B97]). [@B43] generated *Shank1* mutant mice via deletion of exons 14 and 15 encoding almost the entire PDZ domain. This approach resulted in a complete knockout of all SHANK1 protein isoforms. Behavioral studies employing *Shank1^-/-^* mice almost exclusively focused on ASD-related behavioral phenotypes and cognitive deficits with relevance to intellectual disability ([@B90]). Specifically, [@B43] performed an extensive set of cognitive tasks and found that *Shank1^-/-^* mice display impaired contextual but intact cued fear memory, and enhanced acquisition but impaired retention of spatial memory, possibly resembling the aberrant cognitive phenotype present in some ASD cases. Extending these findings, we recently showed that *Shank1^-/-^* mice are severely impaired in novel object recognition memory and that this deficit is associated with increased expression of brain-derived neurotrophic factor BDNF in the hippocampus, possibly due to epigenetic modifications, as indicated by enrichment of histone H3 acetylation at the *Bdnf* promoter1 in *Shank1^-/-^* mice ([@B95]). Consistent with ASD-related behavioral phenotypes, we further showed that *Shank1^-/-^* mice show prominent vocal and olfactory communication deficits ([@B112]; [@B110]; [@B96]), together with a moderate increase in self-grooming behavior ([@B98]) and mild alterations in social behavior ([@B89]; [@B95]).

However, because mutations in *SHANK* genes are associated with multiple major neuropsychiatric disorders, including SCZ and BPD besides ASD, we reasoned that a more comprehensive characterization of *Shank1^-/-^* mice might provide novel insights into the complex role *SHANK1* appears to play. A commonly applied paradigm to assess behavioral phenotypes related to SCZ and BPD in mouse models is psychostimulant-induced hyperactivity ([@B47]; [@B120]). Psychostimulants, such as d-amphetamine (AMPH), can provoke mania-like symptoms in healthy subjects and exacerbate symptoms or induce a manic episode in BPD patients ([@B56]; [@B70]; [@B40]). AMPH-induced hyperactivity is thus considered to be the gold standard for modeling mania-like elevated drive in rodents ([@B4]; [@B36]; [@B71]). While AMPH affects primarily the catecholaminergic system and results in increased extracellular dopamine (DA) and noradrenaline (NA) concentrations through direct interaction with DA and NA transporters, other psychostimulants, such as 3,4-methylenedioxymethamphetamine (MDMA; commonly known as ecstasy), differ in their mode of action by having particularly strong effects on serotonin (5-HT) in addition ([@B94]; [@B44]). Importantly, *Shank3* overexpression was linked to increased locomotor activity in mice and [@B39] found that an acute injection of AMPH aggravated the hyperactivity of *Shank3* overexpressing mice to a greater extent than in controls. Moreover, [@B67] recently generated *Shank2* mutant mice lacking exon 24 (Δ24) and found that *Shank2^Δ24-/-^* mice display elevated levels of locomotor activity, which could be normalized by lithium and valproate treatment, but were further enhanced by AMPH administration. The augmentation with AMPH was more prominent in *Shank2^Δ24-/-^* mice than in wildtype *Shank2^Δ24+/+^* controls ([@B67]).

Here, we therefore asked whether *Shank1* plays a role in the behavioral effects of psychostimulants and whether this is associated with genotype-dependent neurochemical alterations. Firstly, at the behavioral level, we assessed psychostimulant-induced hyperactivity in *Shank1^-/-^* null mutant mice in comparison to heterozygous *Shank1^+/-^* and wildtype *Shank1^+/+^* littermate controls across development. To this aim, juvenile and adult subject mice were treated with the psychostimulant AMPH primarily targeting DA and NA transporters, and their locomotor activity was assessed in an open field. To assess specificity and to evaluate generalizability, subject mice were further treated with the psychostimulant MDMA, which has particularly strong effects on the 5-HT transporter. Secondly, at the neurobiological level, we analyzed DA, NA, and 5-HT neurotransmitter concentrations together with their precursors and metabolites in relevant brain structures, namely prefrontal cortex, nucleus accumbens, and hypothalamus.

Materials and Methods {#s1}
=====================

Animals and Housing
-------------------

Juvenile and adult *Shank1^-/-^* null mutant mice with a targeted replacement of exons 14 and 15 encoding almost the entire PDZ domain were compared to *Shank1^+/-^* heterozygous and *Shank1^+/+^* wildtype littermate control mice. Mice were obtained from mutant lines originally generated by [@B43] on two independent background strains: C57BL/6J and 129SvJae. As high mortality rates were obtained in the C57BL/6J background strain and very low locomotion in the 129SvJae background strain ([@B43]; [@B89]), the two lines were crossed for at least three generations to produce a mixed C57BL/6J/129SvJae background for the *Shank1* mutation. This mixed background was maintained since then and used in the present study, consistent with other studies focusing on this *Shank1* mutant ([@B43]; [@B112]; [@B89]; [@B98], [@B95], [@B97]; [@B110]). Using a heterozygous breeding protocol, *Shank1^+/-^* males and females were bred in a conventional vivarium at the Biomedical Research Center of the Philipps-University of Marburg, Germany. Approximately 2 weeks after pairing for breeding, females were individually housed and inspected daily for pregnancy and delivery. The day of birth was considered as postnatal day (PND) 0. After weaning on PND21, mice were socially housed in groups of 2--6 with same-sex partners in polycarbonate Makrolon type III IVC cages (L × W × H: 420 × 265 × 180 mm, 825 cm^2^; Ehret, Emmendingen, Germany). Bedding and a wooden board were provided in each cage. Standard rodent chow and water were available ad libitum. The colony room was maintained on a 12:12 light/dark cycle (lights on: 06:00h) at approximately 22°C and 40--50% humidity. Pups were identified by paw tattoo, using non-toxic animal tattoo ink (Ketchum permanent Tattoo Inks green paste, Ketchum Manufacturing Inc., Brockville, ON, Canada). The ink was inserted subcutaneously through a 30 gauge hypodermic needle tip into the center of the paw. For genotyping, mouse tail snips were collected by dissecting ∼0.3 cm of tail between PND3-12. Genotyping was performed as described previously ([@B98]). All procedures were approved by the ethical committee of the Regierungspräsidium Gießen, Germany \[file reference: V54--19c 20 15 (1) MR20/35 Nr. 20/2010 and V54--19c 20 15 h 01 MR20/35 Nr. G 30/2018\].

Experimental Design
-------------------

For testing whether *Shank1* plays a role in the behavioral effects of psychostimulants, male and female null mutant *Shank1^-/-^* mice were treated with AMPH (2.5 mg/kg) and MDMA (20 mg/kg), and psychostimulant-induced hyperactivity was compared to heterozygous *Shank1^+/-^* and wildtype *Shank1^+/+^* littermate controls. AMPH-induced hyperactivity was assessed in juvenile (*Shank1^+/+^*: *N* = 15; *Shank1^+/-^*: *N* = 20; *Shank1^-/-^*: *N* = 16) and adult (*Shank1^+/+^*: *N* = 24; *Shank1^+/-^*: *N* = 28; *Shank1^-/-^*: *N* = 28) mice. MDMA-induced hyperactivity was determined in adulthood only (*Shank1^+/+^*: *N* = 14; *Shank1^+/-^*: *N* = 19; *Shank1^-/-^*: *N* = 14). Drug doses are expressed as salt and were determined based on previous studies reporting psychostimulant-induced hyperactivity ([@B78]; [@B119]).

Drug Treatment
--------------

d-amphetamine sulfate (AMPH; Sigma--Aldrich, MO, United States) and 3,4-Methylendioxy-*N*-methylamphetamin (MDMA; Lipomed, Switzerland) were dissolved in 0.9% saline and administered intraperitoneally (i.p.) at volume of 1 ml/kg. As vehicle control, 0.9% saline was used. Injections were performed immediately prior to open field exposure for locomotor activity assessment.

Open Field
----------

Psychostimulant-induced hyperactivity was measured in an open field (50 cm × 50 cm × 35 cm; TSE Systems, Bad Homburg, Germany) under dim red light, according to a previously established protocol ([@B61]). Individual mice were placed randomly in one of the corners of the open field and were allowed to explore the apparatus for 45 min on three consecutive days. On the first day (baseline), mice were habituated to the open field. On the second day (saline), mice were administered saline. On the third day (treatment), mice were administered AMPH or MDMA. Distance traveled, rearing behavior, and the time spent in the center (30 cm × 30 cm) were automatically collected using the TSE VideoMot2 analyzer software (TSE Systems, Bad Homburg, Germany). Circling behavior, i.e., turning in a circular motion, was quantified by a trained observer.

Tissue Preparation
------------------

Drug-naïve juvenile mice of both sexes were individually caged and sacrificed by cervical dislocation. Immediately after the brain was removed, prefrontal cortex, nucleus accumbens, and hypothalamus were dissected using a special brain matrix, designed by Dr. J. Wildmann (Institute for Physiology and Pathophysiology, Philipps-University, Marburg). The different regions were divided into right and left parts, quickly frozen on dry ice, and stored at -80°C until used for neurotransmitter determination.

Neurotransmitter Determination
------------------------------

The concentration of catecholaminergic and indolaminergic neurotransmitters, metabolites, and precursors were measured using high performance liquid chromatography (HPLC), as previously described ([@B79]). Briefly, frozen brain samples were homogenized in 0.4 M HClO~4~ by sonication and 10 μl of the supernatant was injected for the analysis. The HPLC system used consists of a reversed-phase C-18 chromatography column (Supelco, Sigma--Aldrich, St. Louis, MO, United States) as stationary phase and an aqueous eluent containing 10% acetonitrile as mobile phase. Besides the neurotransmitters DA, NA, and 5-HT, the precursors tyrosine (Tyr) and tryptophan (Trp) as well as the metabolites dehydroxyphenylacetic acid (DOPAC), 4-hydroxy-3-methoxy-phenylglycol (MHPG), and 5-hydroxy-indol-acetic acid (5-HIAA) were quantified in each sample. Quantification was done by peak height evaluation or by area integration using Chromeleon software version 6.08 from Dionex (Sunnyvale, CA, United States).

Statistical Analysis
--------------------

Distance traveled in the open field was analyzed using analyses of variance (ANOVAs) for repeated measurements with genotype and sex as between-subject factors and test day or test minute as within-subject factor. Comparison between test days for individual genotypes was performed by calculating paired samples *t*-tests. Neurotransmitter concentrations were analyzed using one-way ANOVAs with genotype as between-subject factor. For each neurotransmitter, values that were smaller than the lower quartile minus three times the interquartile range or larger than the upper quartile plus three times the interquartile range were considered as outliers and excluded from analysis. When appropriate, ANOVAs were followed by LSD *post hoc* analysis for comparing genotypes. A *p*-value of \< 0.050 was considered statistically significant.

Results
=======

AMPH-Induced Hyperactivity
--------------------------

AMPH administration induced hyperactivity in juvenile mice (*F*~2,90~ = 20.840, *p* \< 0.001), as evidenced by representative locomotor activity patterns in response to AMPH on test day 3 in comparison to saline on day 2 (Figure [1A](#F1){ref-type="fig"}). Importantly, there was also an overall effect of genotype (*F*~2,45~ = 4.766, *p* = 0.013; day × genotype: *F*~4,90~ = 0.775, *p* = 0.545), but no general sex effect and no sex interaction with AMPH treatment (*F*~1,45~ = 0.139, *p* = 0.711; sex × genotype: *F*~2,45~ = 0.032, *p* = 0.968; day × sex: *F*~2,90~ = 0.198, *p* = 0.821; day × sex × genotype: *F*~4,90~ = 0.428, *p* = 0.788). A comparison between test days revealed that the distanced traveled following AMPH treatment was clearly higher than the day before in response to saline (*p* \< 0.001; Figure [1B](#F1){ref-type="fig"}). This difference held true for individual genotypes (*Shank1^+/+^*: *t*~14~ = 3.787, *p* = 0.001, one-tailed; *Shank1^+/-^*: *t*~19~ = 2.953, *p* = 0.008; *Shank1^-/-^*: *t*~15~ = 2.495, *p* = 0.025; Figure [1B](#F1){ref-type="fig"}′). When comparing locomotor activity between individual genotypes separately for each test day, evidence for genotype-dependent differences in the distance traveled was obtained under baseline conditions (*F*~2,48~ = 6.619, *p* = 0.003; Figure [2A](#F2){ref-type="fig"}) and in response to saline (*F*~2,48~ = 5.076, *p* = 0.010; Figure [2B](#F2){ref-type="fig"}). Specifically, on day 1, *Shank1^+/+^* mice displayed slightly higher levels of locomotor activity than *Shank1^-/-^* mice (*p* = 0.001) but did not differ significantly from *Shank1^+/-^* mice (*p* = 0.059). Similarly, on day 2, *Shank1^+/+^* mice engaged more in locomotor activity than *Shank1^-/-^* (*p* = 0.004) and *Shank1^+/-^* mice (*p* = 0.019). Locomotor activity displayed by *Shank1^+/-^* and *Shank1^-/-^* mice did not differ from each other under baseline conditions (*p* = 0.059) and in response to saline (*p* = 0.428). Although there was only a trend for a genotype effect on AMPH-induced hyperactivity on the third test day and the overall level of locomotor activity was not significantly affected by *Shank1* deletion (*F*~2,48~ = 2.602, *p* = 0.085), the temporal response pattern differed between genotypes (genotype: *F*~2,45~ = 2.186, *p* = 0.124; time × genotype: *F*~88,1980~ = 1.278, *p* = 0.045; Figure [2C](#F2){ref-type="fig"}). After about 10 min with similar locomotor activity levels in all genotypes, *Shank1^+/+^* mice displayed a strong increase in locomotor activity and maintained high activity levels for about 30 min, whereas the AMPH-induced increase was less prominent in *Shank1^+/-^* and *Shank1^-/-^* mice (Figures [2A′--C′](#F2){ref-type="fig"}).

![AMPH-induced hyperactivity in juvenile *Shank1* mice. **(A)** Exemplary figure depicting the locomotor activity pattern of individual juvenile *Shank1^+/+^, Shank1^+/-^*, and *Shank1^-/-^* mice injected with saline (NaCl) on day 2 (upper panel) and with AMPH on day 3 (lower panel); measured over 45 min. **(B)** Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after AMPH treatment (green bar). **(B′)** Line graph depicting the distance traveled by *Shank1^+/+^* (black circle), *Shank1^+/-^* (white circle), and *Shank1^-/-^* (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. ^\#\#^*p* \< 0.001 **(B)**, ^\#^*p* \< 0.05 vs. day 2 **(B′)**.](fnmol-11-00419-g001){#F1}

![AMPH-induced hyperactivity in juvenile *Shank1* mice. **(A--C)** Bar graphs and **(A′--C′)** line graphs depicting the distance traveled by *Shank1^+/+^* (black bar/black circle), *Shank1^+/-^* (striped bar/white circle), and *Shank1^-/-^* (white bar/black triangle). Locomotor activity was compared during baseline testing **(A,A′)**, following saline administration **(B,B′)**, and after AMPH treatment **(C,C′)**. Data are presented as means + SEM or means ± SEM. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.001.](fnmol-11-00419-g002){#F2}

Of note, the time spent in the center of the open field was also affected and changed across test days (*F*~2,90~ = 33.804, *p* \< 0.001). There were overall effects of genotype (*F*~2,45~ = 9.573, *p* \< 0.001; day × genotype: *F*~4,90~ = 2.774, *p* = 0.032) and sex (*F*~1,45~ = 7.393, *p* = 0.009; sex × genotype: *F*~2,45~ = 0.091, *p* = 0.914), but no sex interaction with AMPH treatment (day × sex: *F*~2,90~ = 0.352, *p* = 0.704; day × sex × genotype: *F*~4,90~ = 0.188, *p* = 0.944). When comparing the time spent in the center between individual genotypes separately for each test day, prominent genotype differences were detected across all three test days. Specifically, under baseline conditions, genotypes differed from each other (*F*~2,48~ = 9.360, *p* \< 0.001; Supplementary Figure [1A](#SM1){ref-type="supplementary-material"}) and *Shank1^+/+^* mice spent more time in the center than *Shank1^+/-^* (*p* = 0.018) and *Shank1^-/-^* mice (*p* \< 0.001), with the latter also differing from each other (*p* = 0.037). Similarly, center time differed between genotypes in response to saline on day 2 (*F*~2,48~ = 4.388, *p* = 0.018; Supplementary Figure [1B](#SM1){ref-type="supplementary-material"}), with *Shank1^+/+^* mice again spending more time in the center than *Shank1^+/-^* (*p* = 0.015) and *Shank1^-/-^* mice (*p* = 0.010), but the latter not differing from each other (*p* = 0.774). A similar pattern was obtained also in response to AMPH on day 3 (*F*~2,48~ = 5.367, *p* = 0.008; Supplementary Figure [1C](#SM1){ref-type="supplementary-material"}), with *Shank1^+/+^* mice spending more time in the center than *Shank1^+/-^* (*p* = 0.011) and *Shank1^-/-^* mice (*p* = 0.004), but the latter not differing from each other (*p* = 0.546).

Consistent with the data obtained in juveniles, AMPH administration induced hyperactivity in adult mice (*F*~2,148~ = 107.888, *p* \< 0.001), and this is similarly evidenced by representative locomotor activity patterns on test day 3 in comparison to saline on day 2 (Figure [3A](#F3){ref-type="fig"}). Again, there was a general genotype effect (*F*~2,74~ = 10.233, *p* \< 0.001), while sex had no prominent impact and did not modulate AMPH effects in a genotype-dependent manner (*F*~1,74~ = 3.358, *p* = 0.064; sex × genotype: *F*~2,74~ = 0.349, *p* = 0.707; day × sex: *F*~2,148~ = 3.324, *p* = 0.039; day × sex × genotype: *F*~4,148~ = 0.957, *p* = 0.433). This was further supported by a comparison between test days that revealed clearly higher levels of locomotor activity following AMPH treatment than the day before in response to saline (*p* \< 0.001; Figure [3B](#F3){ref-type="fig"}) and this difference held true for individual genotypes (*Shank1^+/+^*: *t*~23~ = 5.800, *p* \< 0.001, one-tailed; *Shank1^+/-^*: *t*~27~ = 8.478, *p* \< 0.001; *Shank1^-/-^*: *t*~27~ = 5.123, *p* \< 0.001; Figure [3B](#F3){ref-type="fig"}′). Despite this general effect, however, AMPH responsivity in adult mice was strongly affected by *Shank1* deletion (day × genotype: *F*~4,148~ = 10.030, *p* \< 0.001). While locomotor activity did not differ between genotypes under baseline conditions (*F*~2,77~ = 0.980, *p* = 0.380; Figure [4A](#F4){ref-type="fig"}) and no differences were evident in response to saline (*F*~2,77~ = 0.801, *p* = 0.453; Figure [4B](#F4){ref-type="fig"}), prominent genotype differences were evident following AMPH treatment. In contrast to juvenile mice, AMPH-induced hyperactivity was clearly dependent on genotype in adult mice (*F*~2,77~ = 10.449, *p* \< 0.001). Specifically, in comparison to *Shank1^-/-^* mice, there was increased hyperactivity in *Shank1^+/+^* (*p* \< 0.001) and *Shank1^+/-^* mice (*p* \< 0.001) following AMPH treatment, whereas AMPH-induced hyperactivity did not differ between *Shank1^+/+^* and *Shank1^+/-^* mice (*p* = 0.768). This prominent genotype effect was also reflected in the temporal response pattern (genotype: *F*~2,77~ = 10.449, *p* \< 0.001; time × genotype: *F*~88,3388~ = 6.004, *p* \< 0.001; Figure [4C](#F4){ref-type="fig"}). After about 10 min with similar locomotor activity levels in all genotypes, *Shank1^+/+^* and *Shank1^+/-^* mice displayed a strong increase in locomotor activity and maintained high activity levels until the end of testing, whereas the AMPH-induced increase was very mild in *Shank1^-/-^* mice (Figures [4A′--C′](#F4){ref-type="fig"}).

![**(A)** AMPH-induced hyperactivity in adult *Shank1* mice. Exemplary figure depicting the locomotor activity pattern of individual adult *Shank1^+/+^, Shank1^+/-^*, and *Shank1^-/-^* mice injected with saline (NaCl) on day 2 (upper panel) and with AMPH on day 3 (lower panel); measured over 45 min. **(B)** Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after AMPH treatment (green bar). **(B′)** Line graph depicting the distance traveled by *Shank1^+/+^* (black circle), *Shank1^+/-^* (white circle), and *Shank1^-/-^* (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. ^\#\#^*p* \< 0.001 **(B)**, ^\#\#^*p* \< 0.001 vs. day 2 **(B′)**.](fnmol-11-00419-g003){#F3}

![AMPH-induced hyperactivity in adult *Shank1* mice. **(A--C)** Bar graphs and **(A′--C′)** line graphs depicting the distance traveled by *Shank1^+/+^* (black bar/black circle), *Shank1^+/-^* (striped bar/white circle), and *Shank1^-/-^* (white bar/black triangle). Locomotor activity was compared during baseline testing **(A,A′)**, following saline administration **(B,B′)**, and after AMPH treatment **(C,C′)**. Data are presented as means + SEM or means ± SEM. ^∗∗^*p* \< 0.001.](fnmol-11-00419-g004){#F4}

Because *Shank1* deletion had prominent effects on the induction of locomotor activity following AMPH treatment in *Shank1^-/-^* mice but not *Shank1^+/-^* mice, we also tested whether rearing behavior was affected by genotype in a similar manner in adult mice. AMPH administration induced rearing behavior (*F*~2,148~ = 3.885, *p* = 0.023) and, alike locomotor activity, there was a general genotype effect on rearing behavior (*F*~2,74~ = 7.794, *p* \< 0.001). Sex had no prominent impact and did not modulate AMPH effects (*F*~1,74~ = 0.179, *p* = 0.674; sex × genotype: *F*~2,74~ = 0.578, *p* = 0.536; day × sex: *F*~4,148~ = 0.544, *p* = 0.582; day × sex × genotype: *F*~4,148~ = 1.815, *p* = 0.129). Importantly, however, AMPH responsivity was again strongly affected by *Shank1* deletion (day × genotype: *F*~4,148~ = 2.926, *p* = 0.023). While rearing behavior did not differ between genotypes under baseline conditions (*F*~2,77~ = 1.163, *p* = 0.318; Supplementary Figure [2A](#SM2){ref-type="supplementary-material"}) and no differences were evident in response to saline (*F*~2,77~ = 1.406, *p* = 0.251; Supplementary Figure [2B](#SM2){ref-type="supplementary-material"}), prominent genotype differences were evident following AMPH treatment (*F*~2,77~ = 8.629, *p* \< 0.001). Specifically, in comparison to *Shank1^+/+^* mice, there was reduced rearing behavior in *Shank1^+/-^* (*p* \< 0.001) and *Shank1^-/-^* mice (*p* \< 0.001) following AMPH treatment, whereas AMPH-induced rearing behavior did not differ between *Shank1^+/-^* and *Shank1^-/-^* mice (*p* = 0.788). This prominent genotype effect was also reflected in the temporal response pattern (genotype: *F*~2,77~ = 8.629, *p* \< 0.001; time × genotype: *F*~88,3388~ = 2.040, *p* \< 0.001; Supplementary Figure [2C](#SM2){ref-type="supplementary-material"}). After about 10 min with similar levels of rearing behavior in all genotypes, only *Shank1^+/+^* mice displayed a strong increase in rearing behavior and maintained high rearing levels until the end of testing, whereas the AMPH-induced increase was very mild in *Shank1^+/-^* and *Shank1^-/-^* mice (Supplementary Figures [2A′--C′](#SM2){ref-type="supplementary-material"}).

Of note, the time spent in the center of the open field was also affected and changed across test days (*F*~2,148~ = 30.879, *p* \< 0.001), but no genotype-dependent differences were obtained (*F*~2,74~ = 0.998, *p* = 0.373; day × genotype: *F*~4,148~ = 1.579, *p* = 0.183), with sex having also no impact (*F*~1,74~ = 0.270, *p* = 0.605; sex × genotype: *F*~2,74~ = 0.138, *p* = 0.871; day × sex: *F*~2,148~ = 1.543, *p* = 0.217; day × sex × genotype: *F*~4,148~ = 0.660, *p* = 0.621). When comparing genotypes on individual test days, no differences were observed under baseline conditions (*F*~2,77~ = 0.573, *p* = 0.566; Supplementary Figure [3A](#SM3){ref-type="supplementary-material"}) and in response to saline on day 2 (*F*~2,77~ = 2.590, *p* = 0.082; Supplementary Figure [3B](#SM3){ref-type="supplementary-material"}), whereas genotypes differed from each other in response to AMPH on day 3 (*F*~2,77~ = 4.318, *p* = 0.017; Supplementary Figure [3C](#SM3){ref-type="supplementary-material"}). Specifically, *Shank1^+/-^* mice spent less time in the center than *Shank1^+/+^* mice (*p* = 0.005) but not than *Shank1^-/-^* mice (*p* = 0.055), with the latter also not differing from each other (*p* = 0.324).

MDMA-Induced Hyperactivity
--------------------------

MDMA administration induced hyperactivity in adult mice (*F*~2,82~ = 9.290, *p* \< 0.001), as again evidenced by representative locomotor activity patterns in response to MDMA on test day 3 in comparison to saline on day 2 (Figure [5A](#F5){ref-type="fig"}). Consistent with AMPH, there was a general genotype effect (*F*~2,41~ = 13.153, *p* \< 0.001), with sex having no prominent impact in modulating MDMA effects (*F*~1,41~ = 0.689, *p* = 0.411; sex × genotype: *F*~2,41~ = 4.155, *p* = 0.023; day × sex: *F*~2,82~ = 2.487, *p* = 0.089; day × sex × genotype: *F*~4,82~ = 0.534, *p* = 0.711). Again, this was further supported by a comparison between test days that revealed clearly higher levels of locomotor activity following MDMA treatment than the day before in response to saline (*p* = 0.003; Figure [5B](#F5){ref-type="fig"}). However, despite this difference held true for *Shank1^+/+^* (*t*~13~ = 2.000, *p* = 0.034, one-tailed) and *Shank1^+/-^* mice (*t*~18~ = 3.356, *p* = 0.004), no evidence for MDMA-induced hyperactivity was evident in *Shank1^-/-^* mice, with their level of locomotor activity being the same following MDMA as in response to saline (*t*~13~ = 1.188, *p* = 0.256; Figure [5B′](#F5){ref-type="fig"}). In fact, similar to AMPH, although more prominent, MDMA responsivity in adult mice was strongly affected by *Shank1* deletion (day × genotype: *F*~4,82~ = 2.759, *p* = 0.033) and clear genotype differences in hyperactivity following MDMA administration were evident (*F*~2,44~ = 6.606, *p* = 0.003). Importantly, the lack of MDMA-induced hyperactivity in *Shank1^-/-^* mice was not driven by baseline differences in locomotor activity. Although genotype differences were evident under baseline conditions (*F*~2,44~ = 8.286, *p* = 0.001; Figure [6A](#F6){ref-type="fig"}) and *Shank1^-/-^* mice displayed lower locomotor activity compared to *Shank1^+/+^* (*p* \< 0.001) and *Shank1^+/-^* mice (*p* = 0.040), with the latter also differing from each other (*p* = 0.029), locomotor activity did not differ between genotypes in response to saline (*F*~2,44~ = 2.445, *p* = 0.098; Figure [6B](#F6){ref-type="fig"}). Specifically, as compared to *Shank1^-/-^* mice, increased MDMA-induced hyperactivity was detected in *Shank1^+/+^* (*p* = 0.002) and *Shank1^+/-^* mice (*p* = 0.004), whereas the latter two did not differ from each other (*p* = 0.652). This prominent genotype effect was also reflected in the temporal response pattern (genotype: *F*~2,44~ = 6.606, *p* = 0.003; time × genotype: *F*~88,1936~ = 0.999, *p* = 0.484; Figure [6C](#F6){ref-type="fig"}). While locomotor activity levels increased in *Shank1^+/+^* and *Shank1^+/-^* mice already from the very beginning of testing, MDMA treatment in *Shank1^-/-^* mice was associated with a decrease of locomotor activity, with very low activity levels being maintained in *Shank1^-/-^* mice throughout testing (Figures [6A′--C′](#F6){ref-type="fig"}).

![MDMA-induced hyperactivity in adult *Shank1* mice. **(A)** Exemplary figure depicting the locomotor activity pattern of individual adult *Shank1^+/+^, Shank1^+/-^*, and *Shank1^-/-^* mice injected with saline (NaCl) on day 2 (upper panel) and with MDMA on day 3 (lower panel); measured over 45 min. **(B)** Bar graph depicting the distance traveled by all genotypes during baseline testing (white bar), following saline administration (blue bar), and after MDMA treatment (orange bar). **(B′)** Line graph depicting the distance traveled by *Shank1^+/+^* (black circle), *Shank1^+/-^* (white circle), and *Shank1^-/-^* (black triangle) over the three consecutive test days. Data are presented as means + SEM or means ± SEM. ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.001 **(B)**, ^\#^*p* \< 0.05 vs. day 2 **(B′)**.](fnmol-11-00419-g005){#F5}

![MDMA-induced hyperactivity in adult *Shank1* mice. **(A--C)** Bar graphs and **(A′--C′)** line graphs depicting the distance traveled by *Shank1^+/+^* (black bar/black circle), *Shank1^+/-^* (striped bar/white circle), and *Shank1^-/-^* (white bar/black triangle). Locomotor activity was compared during baseline testing **(A,A′)**, following saline administration **(B,B′)**, and after MDMA treatment **(C,C′)**. Data are presented as means + SEM or means ± SEM. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.001.](fnmol-11-00419-g006){#F6}

Of note, the time spent in the center of the open field was also affected and changed across test days (*F*~2,82~ = 43.972, *p* \< 0.001), and genotype-dependent differences were obtained (*F*~2,41~ = 5.374, *p* = 0.008; day × genotype: *F*~4,82~ = 3.264, *p* = 0.016), with sex having no impact (*F*~1,41~ = 0.001, *p* = 0.978; sex × genotype: *F*~2,41~ = 0.823, *p* = 0.446 day × sex: *F*~2,82~ = 0.061, *p* = 0.941; day × sex × genotype: *F*~4,82~ = 0.148, *p* = 0.963). When comparing genotypes on individual test days, genotype differences were evident under baseline conditions (*F*~2,44~ = 5.505, *p* = 0.007; Supplementary Figure [4A](#SM4){ref-type="supplementary-material"}). Specifically, *Shank1^+/+^* mice spent more time in the center than *Shank1^+/-^* (*p* = 0.005) and *Shank1^-/-^* mice (*p* = 0.006), with the latter not differing from each other (*p* = 0.883). Genotypes did not differ from each other in terms of the time spent in the center on day 2 in response to saline (*F*~2,44~ = 1.537, *p* = 0.226; Supplementary Figure [4B](#SM4){ref-type="supplementary-material"}), and on day 3 in response to MDMA (*F*~2,44~ = 1.170, *p* = 0.320; Supplementary Figure [4C](#SM4){ref-type="supplementary-material"}).

Because MDMA-induced hyperactivity was completely absent in *Shank1^-/-^* mice, we also tested the hypothesis that MDMA treatment might have induced repetitive and stereotyped movement patterns, such as circling behavior ([@B74]; [@B78]). In fact, there was an overall increase in repetitive circling behavior following MDMA treatment (*F*~1,41~ = 78.866, *p* \< 0.001). Importantly, however, the increase in circling occurred irrespective of genotype and can thus not explain the lack of MDMA-induced hyperactivity in *Shank1^-/-^* mice. Specifically, there was no prominent effect of genotype (*F*~2,41~ = 1.925, *p* = 0.159; day × genotype: *F*~2,41~ = 1.678, *p* = 0.199) or sex (*F*~1,41~ = 0.004, *p* = 0.953; sex × genotype: *F*~2,41~ = 1.171, *p* = 0.320; day × sex: *F*~1,41~ = 0.061, *p* = 0.806; day × sex × genotype: *F*~2,41~ = 1.695, *p* = 0.196). A comparison between test days revealed that circling behavior following MDMA treatment was clearly higher than the day before in response to saline (*p* \< 0.001; Supplementary Figure [5A](#SM5){ref-type="supplementary-material"}), yet this increase occurred irrespective of genotype and held true for all individual genotypes (*Shank1^+/+^*: *t*~13~ = 4.283, *p* \< 0.001, one-tailed; *Shank1^+/-^*: *t*~18~ = 7.681, *p* \< 0.001; *Shank1^-/-^*: *t*~27~ = 4.065, *p* = 0.001; Supplementary Figure [5A](#SM5){ref-type="supplementary-material"}′).

Neurotransmitter Measurements
-----------------------------

### Prefrontal Cortex

Concentrations of the DA precursor Tyr in the prefrontal cortex did not differ between genotypes (*F*~2,39~ = 0.364, *p* = 0.697; Figure [7A](#F7){ref-type="fig"}). *Shank1* deletion, however, affected the level of the 5-HT precursor Trp (*F*~2,40~ = 3.933, *p* = 0.028; Figure [7B](#F7){ref-type="fig"}). Specifically, *Shank1^-/-^* mice had higher Trp concentrations in the prefrontal cortex than *Shank1^+/+^* (*p* = 0.019) and *Shank1^+/-^* mice (*p* = 0.018), with the latter two not differing from each other (*p* = 0.910).

![Catecholamine/indolamine, precursor, and metabolite concentrations in the prefrontal cortex of *Shank1* mice. Basal levels of **(A)** Tyrosine (Tyr), **(B)** Tryptophan (Trp), **(C)** Dopamine (DA), **(D)** DA-metabolite dehydroxyphenylacetic acid (DOPAC), **(E)** DOPAC/DA ratio, **(F)** Noradrenaline (NA), **(G)** NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), **(H)** MHPG/NA ratio, **(I)** 5-hydroxytryptamine (5-HT; serotonin), **(J)** 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and **(K)** 5-HIAA/5-HT ratio in *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* mice (white bar). *N* = 10--16 per genotype. Data are presented as means + SEM. ^∗^*p* \< 0.05. Schematic representation of the prefrontal cortex was adapted from [@B68].](fnmol-11-00419-g007){#F7}

Although basal DA levels clearly tended to be lower in *Shank1^-/-^* mice, apparent genotype differences in DA levels did not reach statistical significance (*F*~2,38~ = 3.192, *p* = 0.052; Figure [7C](#F7){ref-type="fig"}), while the concentration of the DA metabolite DOPAC differed between genotypes (*F*~2,40~ = 3.879, *p* = 0.029; Figure [7D](#F7){ref-type="fig"}). *Shank1^+/+^* mice had higher DOPAC concentrations than *Shank1^-/-^* (*p* = 0.008) but not *Shank1^+/-^* mice (*p* = 0.290), with *Shank1^-/-^* and *Shank1^+/-^* mice also not differing from each other (*p* = 0.102). The DOPAC/DA ratio, however, was not affected by *Shank1* deletion (*F*~2,38~ = 0.261, *p* = 0.772; Figure [7E](#F7){ref-type="fig"}).

While DA levels were not significantly affected by genotype, *Shank1* deletion affected basal NA concentrations (*F*~2,35~ = 6.597, *p* = 0.004; Figure [7F](#F7){ref-type="fig"}). *Shank1^-/-^* mice had higher concentrations of NA as compared to *Shank1^+/+^* (*p* = 0.003) and *Shank1^+/-^* mice (*p* = 0.003), while *Shank1^+/+^* and *Shank1^+/-^* mice did not differ in that aspect (*p* = 0.797). There were no differences between genotypes in the concentrations of the NA metabolite MHPG (*F*~2,39~ = 1.604, *p* = 0.214; Figure [7G](#F7){ref-type="fig"}), yet the MHPG/NA ratio differed between genotypes (*F*~2,34~ = 4.066, *p* = 0.026; Figure [7H](#F7){ref-type="fig"}). The MHPG/NA ratio was lower in *Shank1^-/-^* mice as compared to *Shank1^+/-^* mice (*p* = 0.007) but not as compared to *Shank1^+/+^* mice (*p* = 0.140). No significant differences in MHPG/NA ratio between *Shank1^+/+^* and *Shank1^+/-^* mice were detected (*p* = 0.114).

The 5-HT system was not affected by *Shank1* deletion. Specifically, basal 5-HT concentrations, the levels of the main 5-HT metabolite 5-HIAA, and the 5-HIAA/5-HT ratio did not differ between genotypes (all *p*-values \> 0.100; Figures [7I](#F7){ref-type="fig"}--[K](#F7){ref-type="fig"}).

### Nucleus Accumbens

In the nucleus accumbens, *Shank1* deletion affected the concentration of the DA precursor Tyr (*F*~2,40~ = 3.421, *p* = 0.043; Figure [8A](#F8){ref-type="fig"}) and the 5-HT precursor Trp (*F*~2,40~ = 3.709, *p* = 0.033; Figure [8B](#F8){ref-type="fig"}). Specifically, *Shank1^-/-^* mice had higher Tyr concentrations than *Shank1^+/+^* mice (*p* = 0.013) but not *Shank1^+/-^* mice (*p* = 0.281), with the latter also not differing from each other (*p* = 0.143). Trp levels in *Shank1^-/-^* mice were higher than in *Shank1^+/+^* (*p* = 0.018) and *Shank1^+/-^* mice (*p* = 0.028), whereas the latter did not differ from each other (*p* = 0.901).

![Catecholamine/indolamine, precursor, and metabolite concentrations in the nucleus accumbens of *Shank1* mice. Basal levels of **(A)** Tyrosine (Tyr), **(B)** Tryptophan (Trp), **(C)** Dopamine (DA), **(D)** DA-metabolite dehydroxyphenylacetic acid (DOPAC), **(E)** DOPAC/DA ratio, **(F)** Noradrenaline (NA), **(G)** NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), **(H)** MHPG/NA ratio, **(I)** 5-hydroxytryptamine (5-HT; serotonin), **(J)** 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and **(K)** 5-HIAA/5-HT ratio in *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* mice (white bar). *N* = 13--16 per genotype. Data are presented as means + SEM. ^∗^*p* \< 0.05. Schematic representation of the nucleus accumbens was adapted from [@B68].](fnmol-11-00419-g008){#F8}

However, despite genotype differences in the levels of the precursors, there were no differences between genotypes in DA, DOPAC, DOPAC/DA ratio, NA, MHPG, MHPG/NA ratio, 5-HT, 5-HIAA, and 5-HIAA/5-HT ratio (all *p*-values \> 0.100; Figures [8C](#F8){ref-type="fig"}--[K](#F8){ref-type="fig"}).

### Hypothalamus

Concentrations of the precursors Tyr tended to be affected by *Shank1* deletion in the hypothalamus (*F*~2,38~ = 2.902, *p* = 0.067; Figure [9A](#F9){ref-type="fig"}). Trp in the hypothalamus did not differ between genotypes (*F*~2,39~ = 0.864, *p* = 0.429; Figure [9B](#F9){ref-type="fig"}).

![Catecholamine/indolamine, precursor, and metabolite concentrations in the hypothalamus of *Shank1* mice. Basal levels of **(A)** Tyrosine (Tyr), **(B)** Tryptophan (Trp), **(C)** Dopamine (DA), **(D)** DA-metabolite dehydroxyphenylacetic acid (DOPAC), **(E)** DOPAC/DA ratio, **(F)** Noradrenaline (NA), **(G)** NA-metabolite 4-hydroxy-3-methoxy-phenylglycol (MHPG), **(H)** MHPG/NA ratio, **(I)** 5-hydroxytryptamine (5-HT; serotonin), **(J)** 5-HT-metabolite 5-hydroxy-indol-acetic acid (5-HIAA), and **(K)** 5-HIAA/5-HT ratio in *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* mice (white bar). *N* = 12--15 per genotype. Data are presented as means + SEM. ^∗^*p* \< 0.05. Schematic representation of the hypothalamus was adapted from [@B68].](fnmol-11-00419-g009){#F9}

Moreover, the DA system was not affected by *Shank1* deletion. DA, DOPAC, and DOPAC/DA ratio did not differ between genotypes (all *p*-values \> 0.100; Figures [9C](#F9){ref-type="fig"}--[E](#F9){ref-type="fig"}).

While NA concentrations were not affected by *Shank1* deletion (*F*~2,37~ = 0.598, *p* = 0.555; Figure [9F](#F9){ref-type="fig"}), MHPG levels differed between genotypes (*F*~2,37~ = 3.596, *p* = 0.037; Figure [9G](#F9){ref-type="fig"}). Specifically, MHPG concentrations in the hypothalamus of *Shank1^-/-^* mice were higher than *Shank1^+/+^* mice (*p* = 0.012) but not *Shank1^+/-^* mice (*p* = 0.263), with no difference between *Shank1^+/+^* and *Shank1^+/-^* mice (*p* = 0.121). Genotype-dependent differences in the MHPG/NA ratio were not evident (*F*~2,36~ = 1.041, *p* = 0.363; Figure [9H](#F9){ref-type="fig"}).

Finally, there were genotype-dependent differences in 5-HT concentrations in the hypothalamus (*F*~2,38~ = 5.437, *p* = 0.008; Figure [9I](#F9){ref-type="fig"}). While *Shank1^-/-^* mice had higher 5-HT concentrations than *Shank1^+/+^* mice (*p* = 0.002), this difference was not present between *Shank1^-/-^* and *Shank1^+/-^* mice (*p* = 0.113) or between *Shank1^+/+^* and *Shank1^+/-^* mice (*p* = 0.095). In conjunction, there was a trend for differences in 5-HIAA concentrations (*F*~2,38~ = 2.581, *p* = 0.089; Figure [9J](#F9){ref-type="fig"}). No genotype-dependent differences in the 5-HIAA/5-HT ratio were observed (*F*~2,38~ = 0.480, *p* = 0.622; Figure [9K](#F9){ref-type="fig"}).

Discussion
==========

The goal of our present study was to test whether *Shank1* plays a role in the behavioral effects of psychostimulants and whether this is associated with genotype-dependent neurochemical alterations. To this aim, null mutant *Shank1^-/-^* mice were treated with AMPH (2.5 mg/kg) and MDMA (20 mg/kg), and psychostimulant-induced hyperactivity was compared to heterozygous *Shank1^+/-^* and wildtype *Shank1^+/+^* littermate controls. Results show that *Shank1^-/-^* mice display reduced psychostimulant-induced hyperactivity, although psychostimulants robustly stimulated locomotor activity in littermate controls. *Shank1* deletion effects emerged throughout development, were particularly prominent in adulthood, and seen in response to both psychostimulants, i.e., AMPH and MDMA.

Mutations in *SHANK* genes are associated with multiple major neuropsychiatric disorders, including SCZ and BPD besides ASD ([@B38]; [@B6]; [@B12]). Because psychostimulants, such as AMPH, can provoke mania-like symptoms in healthy subjects and exacerbate symptoms or induce a manic episode in BPD patients ([@B56]; [@B70]; [@B40]), we expected that *Shank1* deletion leads to increased AMPH-induced hyperactivity. In fact, AMPH-induced hyperactivity is a commonly applied paradigm to assess behavioral phenotypes related to BPD and considered to be the gold standard for modeling mania-like elevated drive in mouse models ([@B4]; [@B36]; [@B47]; [@B120]). Unexpectedly, however, *Shank1^-/-^* mice displayed reduced psychostimulant-induced hyperactivity. This was reflected in a weaker increase in locomotor activity and a complete lack of induction of rearing behavior following AMPH. Supporting a gene dosage effect, *Shank^+/-^* mice displayed an intermediate phenotype. While locomotor activity was increased following AMPH to levels similar to littermate controls, induction of rearing behavior following AMPH was absent, with rearing levels being similar to *Shank1^-/-^* mice. Our observation that AMPH-induced hyperactivity is reduced rather than enhanced following *Shank1* deletion thus clearly speaks against a behavioral phenotype with relevance to BPD. The lack of a BPD-like phenotype is consistent with currently available human data linking mutations in *SHANK2* and *SHANK3* but not *SHANK1* to BPD. Specifically, a duplication in *SHANK2* has been reported for a BPD patient ([@B62]) and four point mutations in *SHANK2* (c.3979G \> A; c.2900A \> G; c.4461C \> T; c.4926G \> A) have been identified very recently in BPD patients ([@B117]). Moreover, in a substantial number of individuals lacking *SHANK3* and diagnosed with the Phelan-McDermid 22q13 deletion syndrome BPD was evident ([@B92]; [@B108]; [@B13]; [@B101], [@B102]; [@B103]). Notably, *SHANK3* duplications were also associated with BPD in humans ([@B39]). In contrast, mutations in *SHANK1* have been associated with SCZ but not BPD. [@B27] reported a *de novo SHANK1* frameshift mutation in a SCZ patient. [@B48] found that the T allele of the *SHANK1* promotor variant rs3810280 leads to impaired auditory working memory capacity as assessed with digit span in SCZ patients and subjects clinically at risk for developing a psychosis but not in healthy controls.

The clinical pattern is reflected in relevant *Shank* mouse models. For instance, [@B67] recently reported BPD-like phenotypes in *Shank2^Δ24-/-^* mice. Specifically, they observed increased locomotor activity indicative of elevated drive and perturbed circadian rhythms, which could be normalized by lithium and valproate treatment. Importantly, the increase in locomotor activity caused by *Shank2* deletion could be augmented by AMPH administration and the augmentation was more prominent in *Shank2^Δ24-/-^* mice than in *Shank2^Δ24+/+^* controls ([@B67]). *Shank2* deficiency limited to the forebrain recapitulated the BPD-like phenotype, which was associated with alterations in the composition and function of NMDA and AMPA receptors ([@B67]). Moreover, *Shank2^Δ7-/-^* mice likewise display enhanced levels of locomotor activity but augmentation by methylphenidate was weaker in *Shank2^Δ7-/-^* mice than in *Shank2^Δ7+/+^* controls ([@B22]). Finally, *Shank3* overexpression in mice was linked to a BPD-like phenotype characterized by increased locomotor activity and abnormal circadian rhythms ([@B39]). Importantly, hyperactivity of *Shank3* overexpressing mice following an acute injection of AMPH aggravated to a greater extent than in controls. The BPD-like phenotype was rescued by valproate but not lithium treatment. To our knowledge, no studies on *Shank3* deletion effects on AMPH-induced hyperactivity are available. Together, this might suggest that *Shank1* deletion leads to specific alterations in brain structure or function reducing rather than enhancing the efficacy of AMPH to stimulate hyperactivity not present in other relevant *Shank* mouse models.

Sold as speed, AMPH is among the most commonly used illicit drugs, but is also available by prescription and is widely used for treating weight control, narcolepsy, and attention deficit disorder ([@B94]). AMPH acts primarily as a DA and NA releaser by induction of reverse transport of catecholamines through plasma membrane uptake carries, i.e., the DA and NA transporters, and redistribution of catecholamines from synaptic vesicles to the cytosol, with little affinity for receptors ([@B94]; [@B44]), although prominent effects on the 5-HT system were also reported ([@B77]). In mice, the stimulatory effects of AMPH are widely believed to be driven by increased synaptic DA levels and subsequent activation of postsynaptic receptors. In fact, while mice deficient for the NA transporter are supersensitive ([@B114]), AMPH-induced hyperactivity is enhanced in DA transporter overexpressing mice ([@B82]) but completely abolished in mice lacking the DA transporter ([@B35]), an effect mediated by the 5-HT system ([@B28]). Yet, it is not affected by deletion of the gene for the 5-HT transporter ([@B2]), although, to a lesser extent, AMPH affects 5-HT transporters as well ([@B93]; [@B11]). Postsynaptically, AMPH action was reported to depend on D2 but less on D3 and not on D4 receptors, with mixed results for the D1 receptor ([@B115]; [@B55]; [@B23]; [@B24]). Various 5-HT receptors play a modulating role as well and it was shown that AMPH-induced hyperactivity is increased in 5-HT1A ([@B100]), 5-HT1B ([@B7]), and 5-HT2A ([@B83]) receptor knockout mice. Partially conflicting evidence was obtained in pharmacological studies, with 8-OH-DPAT ([@B75]) and SB216641 ([@B76]), 5-HT1A agonist and 5-HT1B antagonist, respectively, reducing AMPH-induced hyperactivity, while CP94,253, a 5-HT1B agonist, further enhances AMPH-induced hyperactivity ([@B76]). Mixed results were obtained for the 5-HT2A ([@B9]; [@B91]) and the 5-HT2C ([@B64]; [@B54]) receptor. For a more comprehensive overview including other species besides mice, the reader is referred to two excellent reviews ([@B44]; [@B60]).

While AMPH-induced hyperactivity was reduced but still detectable in *Shank1^-/-^* mice, MDMA-induced hyperactivity was robustly blocked and completely absent in *Shank1^-/-^* mice. Because a genetic manipulation affecting psychostimulant-induced hyperactivity may easily look like an attenuation when the dose-response curve is in fact shifted to the left, but now producing motor stereotypies instead of ambulation, we measured repetitive circling behavior ([@B74]; [@B78]). We focused on mice treated with MDMA, mostly for two reasons. Firstly, the *Shank1* deletion effect was most prominent in response to MDMA. Secondly, the MDMA dose applied here can be considered relatively high, making it particularly likely that motor stereotypies, such as repetitive circling behavior occur. However, while there was an overall increase in repetitive circling behavior following MDMA treatment, the increase in circling occurred irrespective of genotype and can thus not explain the lack of MDMA-induced hyperactivity in *Shank1^-/-^* mice. Although this speaks against a dose-response curve that is shifted to the left following *Shank1* deletion, a future dose-response study including several MDMA doses appears warranted.

Sold as ecstasy, MDMA is also among the most widely used illicit drugs, yet with little therapeutic use ([@B94]). MDMA acts primarily as a 5-HT and DA releaser by blocking reuptake transporters. However, relative to AMPH, MDMA is more potent at releasing 5-HT than DA ([@B93]; [@B11]). In mice, it was repeatedly shown that MDMA leads to hyperactivity, and hyperactivity induced by low doses of MDMA of up to 10 mg/kg has previously been found to be blocked by deletion of the genes for either the 5-HT1B receptor ([@B86]; [@B45]), the 5-HT2B receptor ([@B17]; [@B16]), or the 5-HT transporter ([@B2]), while it is potentiated in 5-HT2A receptor knockout mice ([@B65]). Consistently, MDMA-induced hyperactivity was reported to be reduced by the 5-HT1B antagonist GR127935 ([@B86]), the 5-HT2B antagonist RS127445 ([@B17]; [@B16]), the 5-HT2C antagonist RS102221 ([@B10]), the 5-HT4 antagonist RS39604 ([@B45]), and the 5-HT uptake inhibitor fluoxetine ([@B25]). Higher MDMA doses, however, induced late-phase increases in hyperactivity in 5-HT1B ([@B86]) and 5-HT2B ([@B16]) receptor knockout mice, possibly due to a delayed increase in DA release ([@B106], [@B107]; [@B116]). [@B78] found that late-phase increases in hyperactivity evoked by MDMA are enhanced in D1 knockout mice but reduced in D2 and D3 knockout mice. In DA transporter knockout mice, the typical hyperactivity displayed by these mice is reduced in response to MDMA ([@B74]). [@B3] reported that MDMA-induced hyperactivity is antagonized by SCH23390, a D1 antagonist. Alike for AMPH, the reader is referred to two excellent reviews for a more comprehensive overview including other species besides mice ([@B94]; [@B60]).

Very little is known about interactions between SHANK1 and the major neurotransmitters affected by AMPH and MDMA, i.e., DA, NA, and 5-HT. [@B1] obtained evidence indicating that in striatal neurons D2 receptors regulate NMDA-mediated neuronal excitation resulting in a depolarized plateau potential and spike firing through a mechanism requiring scaffolding proteins of the SHANK family including SHANK1. [@B8] showed that 3 weeks of treatment with the D2 antagonist haloperidol led to a reduction of SHANK1 mRNA expression in the anterior cingulate cortex and the insula as well as the nucleus accumbens. [@B49] reported that vortioxetine but not fluoxetine treatment leads to enhanced levels of SHANK1 mRNA in the hippocampus. Vortioxetine acts through increasing 5-HT concentrations in the synaptic cleft by inhibiting reuptake and through modulating 5-HT receptors. Finally, [@B66] reported upregulation of SHANK1 mRNA and protein levels in cortex and midbrain following chronic morphine treatment.

In an initial effort to better understand the effects of *Shank1* deletion on the neurochemical architecture, we analyzed DA, NA, and 5-HT neurotransmitter concentrations together with their precursors and metabolites in relevant brain structures, namely prefrontal cortex, nucleus accumbens, and hypothalamus. In the prefrontal cortex, which plays a key role in maintaining inhibitory control over striatal mechanisms involved in the effects of drugs of abuse ([@B21]), basal DA levels tended to be affected by *Shank1* deletion, with lower DA concentrations in *Shank1^-/-^* mice. Moreover, the concentration of the DA metabolite DOPAC differed between genotypes and DOPAC levels were reduced in *Shank1^-/-^* mice. The DOPAC/DA ratio, however, was not affected. Concentrations of the DA precursor Tyr also did not differ between genotypes. Besides DA, basal NA concentrations in the prefrontal cortex were affected by *Shank1* deletion, with higher NA concentrations in *Shank1^-/-^* mice. There were no differences between genotypes in the concentrations of the NA metabolite MHPG, yet the MHPG/NA ratio differed between genotypes and was lower in *Shank1^-/-^* mice. Importantly, the decreased MHPG/NA ratio in *Shank1^-/-^* mice, which was paralleled by increases in NA concentrations in absence of changes in MHPG, might indicate decreased NA metabolism in *Shank1^-/-^* mice. Finally, *Shank1* deletion affected the level of the 5-HT precursor Trp in the prefrontal cortex, with *Shank1^-/-^* mice having higher Trp concentrations. However, basal 5-HT concentrations, the levels of the main 5-HT metabolite 5-HIAA, and the 5-HIAA/5-HT ratio did not differ between genotypes.

In the nucleus accumbens, a key brain structure strongly implicated in the rewarding actions of drugs of abuse ([@B21]), *Shank1* deletion affected the concentration of the DA precursor Tyr and the 5-HT precursor Trp, with the levels of both precursors being higher in *Shank1^-/-^* mice. Despite these genotype differences in the levels of the precursors, DA, NA, and 5-HT concentrations as well as their metabolites were not affected in this brain region.

In the hypothalamus, a brain region less heavily involved in the actions of drugs of abuse ([@B21]), no prominent genotype effects on the levels of the precursors Tyr and Trp were evident and DA, DOPAC as well as the DOPAC/DA ratio also did not differ between genotypes. However, while NA concentrations were not affected by *Shank1* deletion, MHPG levels were higher in the hypothalamus of *Shank1^-/-^* mice. Genotype-dependent differences in the MHPG/NA ratio were not evident. Finally, there were genotype-dependent differences in 5-HT concentrations in the hypothalamus, with *Shank1^-/-^* mice having higher concentrations. In conjunction, there was a trend for a similar genotype pattern in 5-HIAA concentrations. No genotype-dependent differences in the 5-HIAA/5-HT ratio were observed.

Together, this shows that *Shank1* deletion leads to alterations in the neurochemical architecture of the brain regions evaluated, with most prominent effects being evident in the prefrontal cortex. This is remarkable because SHANK1 expression is particularly high in cortex, but low in striatum and hypothalamus ([@B69]), suggesting local effects of *Shank1* deletion. It is tempting to speculate that the opposite alterations in DA and NA concentrations together with the decreased NA metabolism in the prefrontal cortex of *Shank1^-/-^* mice affect the fronto-striatal circuitry in mediating inhibitory control. Reduced prefrontal inhibitory control was strongly implicated in dominance of subcortically mediated responding to drugs of abuse ([@B21]). Of note, the increase of Trp in prefrontal cortex and nucleus accumbens is interesting because the essential amino acid Trp is not only the precursor of 5-HT, but also gives rise to melatonin and kynurenines, which have all been implicated, in one or the other way, in ASD, SCZ, and BPD ([@B58]; [@B80]; [@B33]; [@B50]; [@B20]).

To our knowledge, it is currently not known whether *Shank1* deletion affects the expression and/or function of the AMPH and MDMA targets, i.e., plasma membrane uptake carries for DA, NA, and 5-HT. Because reduced efficacy to stimulate hyperactivity in *Shank1^-/-^* mice is seen in response to both AMPH and MDMA, alterations in the NA transporter are not prime candidates driving the effects. Another candidate for the reduced efficacy of psychostimulants to stimulate hyperactivity in *Shank1^-/-^* mice is the DA transporter. Although reduced expression and/or function of the DA transporter could explain reduced efficacy of psychostimulants, this also appears unlikely to be the case. This is because DA transporter knockout mice display increased locomotor activity under drug free conditions ([@B35]; [@B28]; [@B74]), whereas *Shank1* deletion leads to mild hypoactivity ([@B43]; [@B89]; [@B112]). Finally, the 5-HT transporter appears of relevance because MDMA-induced hyperactivity is abolished in mice lacking the 5-HT transporter ([@B2]), yet this as well does not explain the full result pattern because AMPH-induced hyperactivity is not affected by deletion of the gene for the 5-HT transporter ([@B2]). Of note, the time spent in the center was not affected by AMPH or MDMA treatment in a genotype-dependent manner and the reduction in center time seen following *Shank1* deletion might reflect a mild increase in anxiety levels and is consistent with the literature ([@B43]; [@B89]). Together, this might thus indicate that postsynaptic receptors implicated in psychostimulant-induced hyperactivity, such as D1 and D2 ([@B115]; [@B23]; [@B24]) as well as 5-HT1B ([@B86]; [@B45]) and 5-HT2B ([@B17]; [@B16]) receptors, drive the effects of *Shank1* deletion. However, to our knowledge, there is no study on the expression of relevant receptors in mice lacking SHANK1 available. Future studies on the effects of *Shank1* deletion on DA, NA, and 5-HT transporters and receptors appear therefore warranted.

As master scaffolding proteins enriched in the PSD at excitatory glutamatergic synapses, SHANKs anchor glutamate receptors and link them to the actin cytoskeleton and postsynaptic signaling pathways ([@B99]; [@B81]). In the first study on the effects of *Shank1* deletion, [@B43] focused on the forebrain and hippocampus and demonstrated that *Shank1* is important for regulating dendritic spine morphology and synaptic strength. Standard measures of synaptic plasticity, however, were unchanged, with intact hippocampal long-term potentiation. NMDA, AMPA, and metabotropic glutamate receptors were also not affected ([@B43]). AMPA and NMDA receptors appear to play a role in acquisition and reinstatement of conditioned place preference, as, for instance, induced by MDMA ([@B29]; [@B30]).

More recently, [@B95] studied the effects of *Shank1* deletion on protein expression levels of the brain-derived neurotrophic factor BDNF together with its epigenetic regulation. Partial genetic depletion of BDNF was repeatedly associated with stronger AMPH-induced hyperactivity and associated with increased striatal DA concentrations ([@B15]; [@B85]; [@B51]). Similar findings were obtained for MDMA ([@B59]). [@B95] found that *Shank1* deletion has no effect on basal BDNF expression levels, yet in response to learning a memory task hippocampal BDNF expression was particularly enhanced in *Shank1^-/-^* mice. A subsequent investigation of the epigenetic regulation revealed enrichment of histone H3 acetylation at the *Bdnf* promoter1 in *Shank1^-/-^* mice. Because BDNF is an important regulator of gene expression stimulating D3 receptor expression ([@B37]) and D3 receptor activation was reported to inhibit psychostimulant-induced hyperactivity ([@B55]), altered BDNF expression and its epigenetic regulation might thus be associated with the reduced efficacy of psychostimulants to stimulate hyperactivity in *Shank1^-/-^* mice.

Finally, another relevant factor that possibly contributes to the reduced efficacy of psychostimulants in *Shank1^-/-^* mice might be parvalbumin (PV) expression. PV is a calcium-binding protein important for the maintenance of the excitation/inhibition balance in the brain ([@B42]), repeatedly associated with major neuropsychiatric disorders, including ASD, SCZ, and BPD ([@B53]). Acute AMPH treatment stimulates robust firing of striatal PV-positive GABAergic interneurons ([@B109]). Moreover, AMPH was reported to induce expression of the activity-inducible transcription factor Fos in PV-positive GABAergic interneurons in the nucleus accumbens, together with phosphorylation of the methyl-DNA-binding protein MeCP2 at Ser421 ([@B14]), the latter being associated with SHANK1 protein expression ([@B18]). Very recently, it was further shown that AMPH treatment in mice with silenced PV-positive GABAergic interneurons evoked stronger activation in both D1 and D2 receptor-expressing medium spiny neurons in the nucleus accumbens ([@B104]). Importantly, silencing PV-positive GABAergic interneurons in the nucleus accumbens selectively inhibited the expression of locomotor sensitization following repeated injections of AMPH and blocked AMPH-induced conditioned place preference without affecting AMPH-induced DA release and hyperactivity ([@B104]). This is relevant because SHANK1 protein is highly co-localized with PV-expressing fast-spiking inhibitory interneurons ([@B52]) and *Shank1* deletion was shown to result in reduced PV expression ([@B26]). It would thus be interesting to test whether psychostimulant-induced hyperactivity is altered in PV-deficient mice, which display behavioral phenotypes with relevance to ASD ([@B111]). Specifically, [@B26] found that the reduction of PV-immunoreactive neurons caused by *Shank1* deletion was due to a reduction in *Pvalb* mRNA and PV protein, without any indication for PV-expressing GABAergic interneuron loss. Importantly, PV protein expression levels were selectively decreased in those brain regions normally expressing high levels of SHANK1, such as the somatosensory cortex. However, no evidence for effects of *Shank1* deletion was obtained in the striatum, a region with low SHANK1 expression levels in *Shank1^+/+^* mice, similar to the local effects on neurochemical architecture in the present study.

Conclusion
==========

*Shank1^-/-^* mice display reduced psychostimulant-induced hyperactivity, although psychostimulants robustly stimulated locomotor activity in littermate controls. *Shank1* deletion effects emerged throughout development, were particularly prominent in adulthood, and seen in response to both psychostimulants, i.e., AMPH and MDMA. Specifically, while AMPH-induced hyperactivity was reduced but still detectable in *Shank1^-/-^* mice, MDMA-induced hyperactivity was robustly blocked and completely absent in *Shank1^-/-^* mice. Reduced efficacy of psychostimulants to stimulate hyperactivity in *Shank1^-/-^* mice might be associated with alterations in the neurochemical architecture in prefrontal cortex, nucleus accumbens, and hypothalamus. Our observation that psychostimulant-induced hyperactivity is reduced rather than enhanced in *Shank1^-/-^* mice clearly speaks against a behavioral phenotype with relevance to BPD. Lack of BPD-like phenotype is consistent with currently available human data linking mutations in *SHANK2* and *SHANK3* but not *SHANK1* to BPD.
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###### 

Time spent in the center in juvenile *Shank1* mice treated with AMPH. **(A--C)** Bar graphs depicting the time spent in the center by *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* (white bar). Center time was compared during baseline testing **(A)**, following saline administration **(B)**, and after AMPH treatment **(C)**. Data are presented as means + SEM. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.001.
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Click here for additional data file.

###### 

AMPH-induced rearing behavior in adult *Shank1* mice. **(A--C)** Bar graphs and **(A′--C′)** line graphs depicting the rearing behavior by *Shank1^+/+^* (black bar/black circle), *Shank1^+/-^* (striped bar/white circle), and *Shank1^-/-^* (white bar/black triangle). Rearing behavior was compared during baseline testing **(A,A′)**, following saline administration **(B,B′)**, and after AMPH treatment **(C,C′)**. Data are presented as means + SEM or means ± SEM. ^∗∗^*p* \< 0.001.
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Time spent in the center in adult *Shank1* mice treated with AMPH. **(A--C)** Bar graphs depicting the time spent in the center by *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* (white bar). Center time was compared during baseline testing **(A)**, following saline administration **(B)**, and after AMPH treatment **(C)**. Data are presented as means + SEM. ^∗^*p* \< 0.05.
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###### 

Time spent in the center in adult *Shank1* mice treated with MDMA. **(A--C)** Bar graphs depicting the time spent in the center by *Shank1^+/+^* (black bar), *Shank1^+/-^* (striped bar), and *Shank1^-/-^* (white bar). Center time was compared during baseline testing **(A)**, following saline administration **(B)**, and after MDMA treatment **(C)**. Data are presented as means + SEM. ^∗^*p* \< 0.05.
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###### 

MDMA-induced repetitive and stereotyped circling behavior in adult *Shank1* mice treated with MDMA. **(A)** Bar graph depicting the circling behavior displayed by all genotypes following saline administration (blue bar) and after MDMA treatment (orange bar). **(A′)** Line graph depicting the circling behavior displayed by *Shank1^+/+^* (black circle), *Shank1^+/-^* (white circle), and *Shank1^-/-^* (black triangle) over two consecutive test days, i.e., following saline administration (blue are) and after MDMA treatment (orange area). Data are presented as means + SEM or means ± SEM. ^\#\#^*p* \< 0.001 **(A)**, ^\#^*p* \< 0.05 and ^\#\#^*p* \< 0.001 vs. day 2 **(A′)**.
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Click here for additional data file.
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